Infectious Diseases & Vaccines

Johnson & Johnson is undertaking a multipronged response to the COVID-19 pandemic. We are:

• Accelerating the clinical development of our lead SARS-CoV-2 vaccine candidate, leveraging our AdVac® platform.

• Expanding our manufacturing and distribution capabilities to provide global access to our SARS-CoV-2 vaccine candidate as soon as early 2021.

• Screening a library of compounds and conducting clinical trials to explore potential therapeutics.

In March 2020 we announced a lead COVID-19 vaccine candidate had been identified from constructs that the Company had been working on since January.

In July 2020 we announced the start of our Phase 1/2a first-in-human clinical trial of an investigational SARS-CoV-2 vaccine.

In September 2020 we started larger Phase 3 trials of our vaccine candidate, following review of interim data from Phase 1/2a trials and approval of regulators.

The Phase 3 ENSEMBLE trial of the Janssen COVID-19 Vaccine candidate will recruit up to 60,000 people across three continents and will study the safety and efficacy of a single vaccine dose versus placebo in preventing COVID-19.

Johnson and Johnson is in ongoing discussions with many stakeholders, including national governments and global organisations. We are committed to bringing an affordable vaccine to the public on a not-for-profit basis for emergency pandemic use.

The availability of the Janssen COVID-19 Vaccine candidate in New Zealand is subject to its successful development and regulatory approval by MedSafe.

Our Expertise in Pandemics

Our vaccine development program leverages Janssen’s AdVac® technology that provides the ability to rapidly upscale production of the optimal vaccine candidate.

This is the same technology used in the development and manufacturing of a number of our other vaccines and vaccine candidates.

"There is so much more to be done; Patients are waiting."

Dr Paul Stoffels

CHEIF SCIENTIFIC OFFICER, JOHNSON & JOHNSON

At Janssen we have ambitious goals. To prevent, cure and one day eradicate infectious diseases. It’s a goal we’ve been working toward from our earliest days. Our company’s founder, Dr Paul Janssen, relentlessly pursued solutions to the diseases that threaten humanity, particularly HIV/AIDS.

Today we continue to improve public health by fighting infectious diseases worldwide. Our treatments have helped to transform the lives of people living with HIV/AIDS, hepatitis C and tuberculosis. Success has come through constant innovation and research. But treatments alone are not enough. That’s why we’re working with the doctors, nurses and advocates on the front line to provide a portfolio of solutions.

Joint Initiatives: Working with multiple organisations to improve access to treatment and patient outcomes

Janssen has teamed up with the National Association of People Living With HIV Australia (NAPWHA) and several other pharmaceutical companies to help temporary Australian residents access to antiretroviral treatment.

For patients that do not have access to Government subsidised healthcare, the cost of treatment may be beyond reach.

The joint initiative offered HIV-positive temporary residents who qualify for the program access to free treatment.

Asia-Pacific Programs: Supporting our neighbours’ response to infectious diseases

At Janssen our commitment to improving the lives of people with infectious diseases transcends national boundaries. It’s why we support the Collaboration for Health in Papua New Guinea.

PNG has one of the highest rates of HIV in our region.

Together with our partners, we have launched initiatives designed to assist local health workers and increase access to counseling, advice and services.

Professional Partnerships: Working with key organisations to secure better resources and services for people living with infectious diseases

Janssen supports a wide range of healthcare, community and patient organisations to improve the way we manage and treat infectious diseases.

Our partnerships include the National Association of People Living With HIV Australia (NAPWA), Hepatitis Australia and the Australasian Society for HIV Medicine.